Investigating the role of probiotics in the clearance of high-risk HPV infection

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260502069233N1

Enrollment

150

Registered

2026-05-16

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV infection. High risk human papillomavirus (HPV) DNA test positive from female genital organs

Interventions

Intervention 1: Intervention group: 75 patients with high-risk HPV who, in addition to standard treatment, are treated with the vaginal probiotic Vagifem for three months and the oral probiotic Lactof

Eligibility

Sex/Gender

Female

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with high-risk HPV Age between 25 - 60 years Epithelial involvement CIN1

Exclusion criteria

Exclusion criteria: Not consenting to participate in research pregnant women having immunodeficiency diseases having history of cancer Epithelial involvement CIN2 and3

Design outcomes

Primary

Measure	Time frame
High risk HPV infection clearance. Timepoint: HPV infection clearance test at the beginning of the study and 6 months after the start of the intervention. Method of measurement: Pap smear + Liquid base hpv test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtena Hosseini

Shahid Beheshti University of Medical Sciences

Ffandi361@gmail.com+98 21 7343 2440

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026